Due to a majority of reported cardiotoxic cases occurring in melanoma patients receiving anti-PD-1 ICI, the B16-F10 melanoma cell line was utilized to investigate the efficacy of anti-PD-1 antibodies in treating cancer. Here, PDCD1 is linked to melanoma.